Sheryl K. Elkin

Sheryl K. Elkin

Auto-generated profile, based on publicly available information

Sheryl K. Elkin

QIAGEN, 1001 Marshall St Ste 200, Redwood City, CA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in Cancer Biology & Therapy
Verified
Journal Article
Open access
SISadakatsu Ikeda
Sadakatsu Ikeda
SESheryl K. Elkin
Sheryl K. Elkin
BTBrett N. Tomson
Brett N. Tomson
JCJennifer L. Carter
Jennifer L. Carter
RKRazelle Kurzrock
Razelle Kurzrock
Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer, as well as genomic alterations identified and their potential actionability. Of 4864 patients from multiple institutions for whom NGS was ordered by physicians, only 67 (1.4%) had prostate cancer, representing 1/10 the ordering rate for lung cancer. Prostate cancers harbored 148 unique alterations affecting 63 distinct genes. No two patients had an identical molecular portfolio. The median number of characterized genomic alterations per patient was 3 (range, 1 to 9). Fifty-six of 67 patients (84%) had ≥ 1 potentially actionable alteration. TMPRSS2 fusions affected 28.4% of patients. Genomic aberrations were most frequently detected in TP53 (55.2% of patients), PTEN (29.9%), MYC (17.9%), PIK3CA (13.4%), APC (9.0%), BRCA2 (9.0%), CCND1 (9.0%), and RB1 genes (9.0%). The PI3K (52.2% of patients), WNT (13.5%), DNA repair (17.9%), cell cycle (19.4%), and MAPK (14.9%) machinery were commonly impacted. A minority of patients harbored BRAF, NTRK, ERBB2, or mismatch repair gene abnormalities, which are highly druggable in some cancers. Only ~ 10% of prostate cancer trials (clinicaltrials.gov, year 2017) applied a (non-hormone) biomarker before intervention. In conclusion, though use of clinical-grade NGS is relatively low and only a minority of trials deploy DNA-based biomarkers, many prostate cancer-associated molecular alterations may be pharmacologically tractable with genomcially targeted therapy or, in the case of mismatch repair anomalies, with checkpoint inhibitor immunotherapy.

10 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
PCPhilip R. Cohen
Philip R. Cohen
BTBrett N. Tomson
Brett N. Tomson
SESheryl K. Elkin
Sheryl K. Elkin
EMErica Marchlik
Erica Marchlik
JCJennifer Carter
Jennifer Carter
RKRazelle Kurzrock
Razelle Kurzrock
Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics

6 August 2018 in Nature Biotechnology
Verified
Journal Article
Closed access
KBKathryn D Bungartz
Kathryn D Bungartz
KLKristen Lalowski
Kristen Lalowski
SESheryl K Elkin
Sheryl K Elkin

23 September 2025 in Cancer Genetics
Verified
Journal Article
Open access
AGAarthi Goverdhan
Aarthi Goverdhan
LMLisa Mullineaux
Lisa Mullineaux
APAmber Pryzbylski
Amber Pryzbylski
CTClaire Teigen
Claire Teigen
KHKevin C. Halling
Kevin C. Halling
BPBeth A. Pitel
Beth A. Pitel
Accurate clinical interpretation of somatic cancer variants is critical for diagnosis and guidance of precision oncology treatment. As the depth and breadth of genomic sequencing increased, laboratories developed independent standards for the classification of somatic variants. In response, a set of standards for classification were published by a collaboration among Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC) and Variant Interpretation for Cancer Consortium (VICC). This study evaluated these standards and compared the resulting classifications to the classifications generated by a clinical decision support software system, QIAGEN Clinical Insight (QCI) Interpret One, a system using a version of the 2015 consensus guidelines by the American College of Medical Genetics (ACMG) and Association for Molecular Pathology (AMP) customized for somatic assessment. The published variant set for validation was utilized and expanded by conducting a retrospective analysis using real-world cancer variants drawn from oncology cases tested at Mayo Clinic. For "oncogenic" and "likely oncogenic" variants in the combined datasets, automated classifications by the QCI system were 97.2% concordant with those assessed using the ClinGen/CGC/VICC system. The ClinGen/CGC/VICC standards led to more conservative variant classifications, with a larger proportion of variants assigned to the "variant of unknown significance" and "likely benign" designations. This study demonstrates that the ClinGen/CGC/VICC guidelines and clinical decision support tools can be effectively used together to facilitate somatic variant classification and interpretation.

3 April 2023
Verified
Other
Open access
SKShumei Kato
Shumei Kato
BTBrett N. Tomson
Brett N. Tomson
TBTimon P.H. Buys
Timon P.H. Buys
SESheryl K. Elkin
Sheryl K. Elkin
JCJennifer Carter
Jennifer Carter
RKRazelle Kurzrock
Razelle Kurzrock
Supplemental Table 1. Baseline characteristics of mesothelioma and frequently associated genomic aberrations; Supplemental Table 2. Patient characteristics and molecular profiling of 42 mesothelioma and examples of cognate targeted therapies; Supplemental Table 3. Association between BAP1 aberrations, subtypes of mesothelioma and co-existing molecular alterations; Supplemental Table 4. Association between NF2 aberration, subtypes of mesothelioma and coexisting molecular alterations; Supplemental Table 5. Association between CDKN2A/B loss, subtypes of mesothelioma and co-existing molecular alterations; Supplemental Table 6: Explanations for the examples of theoretical therapies on Table 1. Supplemental Figure 1.(A) Number of genetic aberrations per patient (B) Number of actionable genetic aberrations per patient either with FDA approved therapies or with therapies that are in clinical trial.

3 April 2023
Verified
Other
Open access
THTeresa Helsten
Teresa Helsten
SKShumei Kato
Shumei Kato
MSMaria Schwaederle
Maria Schwaederle
BTBrett N. Tomson
Brett N. Tomson
TBTimon P.H. Buys
Timon P.H. Buys
RKRazelle Kurzrock
Razelle Kurzrock